How CSF Tests May Help Recruitment for Alzheimer’s Drug Clinical Trials
A recent study shows these tests may make it easier and more cost-effective to identify patients for studies of new PET treatments.
Already a member? Log in here
Investment to Advance Test for Diagnosing Early Alzheimer’s Disease
ROCKVILLE, MD — The announcement of a recent investment from Semler Scientific (SMLR) in SYNAPS Dx (SDx), a privately held company focused on the research, development, and commercialization of diagnostics for neurodegenerative disorders and conditions, including...
Leader in Brain Health Sector Achieves Key Certification
ST. LOUIS, MO — C2N Diagnostics has earned ISO 13485:2016 certification for its quality management system. In late 2020 C2N launched the PrecivityAD™ test, an innovative blood test intended for use with patients with cognitive impairment. The test aims to help health...
Studies Show Blood Testing May Be Just as Good If Not Better than PET Scans in Detecting Early Alzheimer’s Disease
...
Already a member? Log in here